Ovarian Cancer Stage IV Clinical Trial
Official title:
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)
The primary objective of this trial is to evaluate the synergistic effects of durvalumab and
tremelimumab plus chemotherapy in advanced-stage ovarian cancer.
Ovarian cancer is the deadliest gynecologic cancer. The current standard therapy is surgical
cytoreduction followed by taxane-platinum combination chemotherapy. However, most patients
with advanced-stage ovarian cancer will experience a relapse of disease. Therefore, there is
an urgent need to improve outcomes of patients with this aggressive cancer.
Research hypothesis: Adding durvalumab and tremelimumab to current neoadjuvant chemotherapy
(front-line therapy) in advanced-stage ovarian cancer can increase response rate and improve
patient's outcome such as progression-free survival and overall survival with minimal effects
on safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
| Completed |
NCT00945191 -
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT03579394 -
Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04701645 -
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
|
Phase 1 | |
| Completed |
NCT03126812 -
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03162562 -
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03922776 -
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer
|
N/A | |
| Completed |
NCT03085238 -
Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04938583 -
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06017557 -
Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR)
|
N/A | |
| Suspended |
NCT05479045 -
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
|
Phase 2 | |
| Completed |
NCT05005650 -
Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
|
||
| Recruiting |
NCT04789694 -
Prehabilitation in Gynaecological Cancer Patients
|
Phase 3 | |
| Not yet recruiting |
NCT05187208 -
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
|
Phase 4 | |
| Recruiting |
NCT06272240 -
Tumor Microenvironment in Ovarian Cancer
|
||
| Not yet recruiting |
NCT06268665 -
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
|
Phase 2 | |
| Active, not recruiting |
NCT03275506 -
PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .
|
Phase 2 | |
| Recruiting |
NCT06290193 -
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery
|
Phase 2 | |
| Completed |
NCT02258165 -
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
|
||
| Recruiting |
NCT03693248 -
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer
|
Phase 3 |